Alaunos Therapeutics, Inc.
TCRTNasdaq
$2.05
↓ -1.0%Jul 17 close · end-of-day
Price
1Y↓ -36.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.0M
Enterprise Value
$3.6M
P/E
—
P/S
1331.4
P/B
3.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$3,000.00
Net Income (TTM)
-$4.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-138166.7%
Net Margin
-136966.7%
ROE
-319.0%
ROIC
-350.6%
Debt / Equity
—
Net Cash
$354,000.00
Return 1Y
-37.1%
Company profile
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.
- CEO
- Kevin S. Boyle
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Texas
- Website
- alaunos.com
Management & directors
- Weis HolgerChief Executive Officer
- Groenewald FerdinandVice President of Finance
Roles derived from SEC Form 4 filings.
Earnings
TCRT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.59↓ -11.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $398,000.00 | $2.9M | $5,000.00 | $10,000.00 | $5,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.8M | -$4.2M |
| Net income | -$80.0M | -$78.8M | -$37.7M | -$4.7M | -$4.7M | -$4.2M |
| Diluted EPS | -$0.38 | -$0.37 | -$2.61 | -$21.97 | -$2.92 | -$2.20 |
| Operating cash flow | -$57.0M | -$61.5M | -$29.2M | -$30.1M | -$5.0M | -$2.9M |
| Free cash flow | -$66.8M | -$64.8M | -$29.4M | -$30.3M | -$5.0M | -$3.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -19484.7% | -1201.4% | -685340.0% | -48120.0% | -84500.0% |
| Net margin | — | -19786.7% | -1291.2% | -93580.0% | -46790.0% | -83520.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4,000.00 | $0.00 | $5,000.00 | $2,000.00 | $0.00 | $0.00 | $3,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.2M | -$1.1M | -$754,000.00 | -$1.1M | -$1.0M | -$1.2M | -$907,000.00 | -$1.0M |
| Net income | -$1.1M | -$1.1M | -$741,000.00 | -$1.1M | -$1.1M | -$1.2M | -$893,000.00 | -$1.0M |
| Diluted EPS | -$0.71 | -$0.70 | -$0.46 | -$0.67 | -$0.63 | -$0.55 | -$0.35 | -$0.59 |
| Operating cash flow | -$1.7M | -$781,000.00 | -$592,000.00 | -$772,000.00 | -$701,000.00 | -$844,000.00 | -$552,000.00 | -$1.0M |
| Free cash flow | -$1.7M | -$781,000.00 | -$592,000.00 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -29150.0% | — | -15080.0% | -54600.0% | — | — | -30233.3% | — |
| Net margin | -28225.0% | — | -14820.0% | -53650.0% | — | — | -29766.7% | — |
Company news
May 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Weis Holger· Chief Executive Officer | Award | 3,880 | $2.26 | $8,768.80 | filing |
| 2026-06-12 | Weis Holger· Chief Executive Officer | Award | 7,761 | $2.26 | $17,539.86 | filing |
| 2026-05-22 | Weis Holger· Chief Executive Officer | Award | 3,700 | $2.37 | $8,769.00 | filing |
| 2026-04-29 | Vieser Jaime | Award | 6,515 | $2.59 | $16,873.85 | filing |
| 2026-04-29 | Postma Robert W | Award | 6,274 | $2.59 | $16,249.66 | filing |
| 2026-04-29 | Jerman Michael Allen | Award | 6,032 | $2.59 | $15,622.88 | filing |
| 2026-01-12 | Vieser Jaime | Award | 5,839 | $2.89 | $16,874.71 | filing |
| 2026-01-12 | Postma Robert W | Award | 5,622 | $2.89 | $16,247.58 | filing |
| 2026-01-12 | Jerman Michael Allen | Award | 5,406 | $2.89 | $15,623.34 | filing |
| 2025-11-21 | Vieser Jaime | Award | 5,340 | $3.16 | $16,874.40 | filing |
| 2025-11-21 | Postma Robert W | Award | 5,142 | $3.16 | $16,248.72 | filing |
| 2025-11-21 | Jerman Michael Allen | Award | 4,183 | $3.16 | $13,218.28 | filing |
| 2025-08-18 | Groenewald Ferdinand· Vice President of Finance | Award | 10,775 | $0.00 | $0.00 | filing |
| 2025-07-03 | Postma Robert W | Award | 4,050 | $0.00 | $0.00 | filing |
| 2025-07-03 | Vieser Jaime | Award | 3,400 | $0.00 | $0.00 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.